1:20 pm Pharmacyclics confirms FDA approval of IMBRUVICA (ibrutinib) as a single agent for patients with chronic lymphocytic leukemia who have received at least one prior therapy – HedgeChatter

1:20 pm Pharmacyclics confirms FDA approval of IMBRUVICA (ibrutinib) as a single agent for patients with chronic lymphocytic leukemia who have received at least one prior therapy

12 Feb

1:20 pm Pharmacyclics confirms FDA approval of IMBRUVICA (ibrutinib) as a single agent for patients with chronic lymphocytic leukemia who have received at least one prior therapy

Bystocknews PCYC, stock Comments Off

View todays social media effects on PCYC

View the latest stocks trending across Twitter. Click to view dashboard

See who Pharmacyclics is hiring next, click here to view

Author